Abstract
Diabetic nephropathy is the leading cause of chronic kidney disease and is associated with increased cardiovascular mortality. Diabetic nephropathy has been classically defined by the presence of proteinuria >0.5 g/24 h. This stage has been referred to as overt nephropathy, clinical nephropathy, proteinuria, or macro albuminuria. It seems to occur as a result of an interaction between metabolic and hemodynamic factors. Hyperglycemia induces oxidative stress and leads to activation of multiple biochemical pathways which are the source of renal damage. Limited therapies are available as a symptomatic treatment which empathize the need for more therapies to treat diabetic nephropathy. Monoamine oxidase (MAO) and its substrates are found in both the exocrine and endocrine parts of pancreatic beta cells. Many studies have showed that MAO-catalyzed reaction may cause structural damage to pancreatic beta cells resulting in disturbances in catecholamine’s metabolism and MAO also generate reactive oxygen species, which plays important role in pathogenesis of diabetic complications. Therefore inhibition of MAO can lead to the secretion of insulin. Thus the purpose of this review is to cover the role of MAO inhibitors as the new therapeutic approach in diabetic nephropathy.
